EN zh-TW

newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / / Markets Insider

Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $363.33, a 10.16% upside from current levels.

Raymond James assigned a Hold rating to Amgen in a report released yesterday.

KEY POINTS
COMPANIES
Read the full story on Markets Insider → →
Share X LinkedIn

Summarized by Newsio from Markets Insider. How we summarize →

RELATED 03
biotech · news · 2h 202

Early ctDNA assessment may help identify patients with locally advanced or oligometastatic non-small cell lung cancer who have markedly different survival outcomes after radiotherapy.

  • Early ctFE measurement during days 10–14 of radiotherapy can stratify survival outcomes in NSCLC patients.
  • ctFE outperformed maximum variant allele frequency and ctDNA detectability as a prognostic biomarker.
Oncodaily →
genai · news · 4h 211

MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today launched ReefIQ™.

  • MindWalk launched ReefIQ, a HYFT-powered biological context layer for AI-driven drug discovery workflows.
  • ReefIQ links fragmented client discovery data into MindWalk's governed, queryable biological context foundation.
Business Wire →
biotech · news · 5h 202

Cancer cells can stay hidden in the body for years before causing a relapse.

  • Breast cancer cells mimic healthy stem cells to survive undetected in bone marrow niches.
  • Notch2, but not Notch1, plays a significant role in inducing dormancy within breast cancer cells.
Drug Target Review →